BNP Paribas Financial Markets
ATNM icon

BNP Paribas Financial Markets’s Actinium Pharmaceuticals ATNM Stock Holding History

BNP Paribas Financial Markets’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197 Sell
201
-36
-15% -$42 ﹤0.01% 5752
2026
Q1 		$236 Hold
237
– – ﹤0.01% 5615
2025
Q4 		$322 Hold
237
– – ﹤0.01% 5520
2025
Q3 		$379 Sell
237
-1,150
-83% -$1.87K ﹤0.01% 5335
2025
Q2 		$1.94K Sell
1,387
-446
-24% -$667 ﹤0.01% 5060
2025
Q1 		$2.95K Sell
1,833
-3,911
-68% -$4.96K ﹤0.01% 4931
2024
Q4 		$7.24K Buy
+5,744
New +$8.91K ﹤0.01% 4889
2015
Q2 		– Sell
-37
Closed -$2.75K – 3546
2015
Q1 		$2.75K Buy
+37
New +$4.4K ﹤0.01% 3409
2014
Q4 		– Sell
-46
Closed -$9.15K – 2068
2014
Q3 		$9.15K Buy
+46
New +$9.12K ﹤0.01% 3630

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BNP Paribas Financial Markets's ATNM Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Actinium Pharmaceuticals (ATNM) stake by 15% in Q2 2026, selling an estimated $42 and leaving 201 shares worth $197. The position accounts for ﹤0.01% of the portfolio, ranked #5752.

BNP Paribas Financial Markets first reported a position in ATNM in Q3 2014 and has held it in 9 quarters since. The position peaked at $9.15K in Q3 2014. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • BNP Paribas Financial Markets held 201 shares of Actinium Pharmaceuticals worth $197 as of Q2 2026.
  • BNP Paribas Financial Markets sold 36 Actinium Pharmaceuticals shares in Q2 2026, an estimated $42.
  • Actinium Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5752 holding.
  • BNP Paribas Financial Markets first reported a position in Actinium Pharmaceuticals in Q3 2014 and has held it in 9 quarters since.
  • BNP Paribas Financial Markets's Actinium Pharmaceuticals position peaked at $9.15K in Q3 2014.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.